After Denali Therapeutics (DNLI) reported DNL343 did not meet the primary or key secondary endpoints in the Phase 2/3 HEALEY trial in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback